Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
- 124 Downloads
Background: Gemcitabine (G) has shown activity in mantle cell lymphoma (MCL) as a single agent. The combination of mitoxantrone (M) and rituximab (R) is also active in MCL. The primary objective of this study was to determine the efficacy of G+M+R in relapsed or refractory MCL. Patients and Methods: Sixteen patients were enrolled between April 2005 and January 2007, 88% had Stage IV MCL, Median patient age was 74 years. Patients received gemcitabine 900 mg/m2 IV (30–60 min infusion) on Days 1 and 8, mitoxantrone 10 mg/m2 IV (5–10 min infusion) on day 1, and rituximab 375 mg/m2 IV on Day 1 (max 400 mg/hour) of the 21-day cycle. Patients received a median of 6 cycles (range, 1–8). Results: Best responses were CR 20% (95%CI, 0, 40.2), PR 27% (95%CI, 4.3, 49.1), SD 40% (95%CI, 15.2, 64.8), and PD 13% (95%CI, 0, 30.5). Median survival and PFS have not been reached with a median follow-up of 10.7 months. The most common Grade 3–4 toxicities were neutropenia (100%), thrombocytopenia (67%), leukopenia (53%), and anemia (33%). The study was closed early due to slow accrual owing to an alternative treatment which became available at the time. Conclusion: The combination of G+M+R in MCL was well-tolerated with manageable toxicity using growth factors to minimize neutropenia; further studies are warranted.
KeywordsMulticenter Community-based Lymphoma Phase II
We thank the patients who participated in this clinical trial, US Oncology physicians, the site coordinators, and data reviewers Denise Elmore-Lockheed, AA, Crystal Grant, BS, Tracy Locke, BS, Jessica Donato, MPH, for help with the statistical analysis, and Kristi A. Boehm, MS, and Maren K. Levin, MS, for editing and writing assistance. Research support was provided by Eli Lilly and Company, Indianapolis IN, USA.
- 2.Jaffe E, Harris N, Stein H, Vardiman JW (eds) (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, FranceGoogle Scholar
- 5.Lenz G, Dreyling M, Hoster E et al (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23(9):1984–1992 doi: 10.1200/JCO.2005.08.133 PubMedCrossRefGoogle Scholar
- 6.National Comprehensive Cancer Network (NCCN) NCCN Clinical practice guidelines in oncology: Non-hodgkin’s lymphoma, v.2.2008. http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf
- 7.National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Non-hodgkin’s lymphoma, v.1.2005 (effective 6/21/05).Google Scholar
- 14.Foran JM, Rohatiner AZ, Cunningham D et al (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18(2):317–324PubMedGoogle Scholar
- 16.Fortstpointner R, Dreyling M, Repp R et al (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104(10):3064–3071 doi: 10.1182/blood-2004-04-1323 CrossRefGoogle Scholar
- 19.Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. JASA 53:457–481Google Scholar
- 23.National Cancer Institute FDA Approval for Bortezomib. http://www.cancer.gov/cancertopics/druginfo/fda-bortezomib (accessed February 12, 2008)